C9orf100 Inhibitors
Rho guanine nucleotide exchange factor 39 (RhoGEF39), encoded by the gene ARHGEF39, belongs to the RhoGEF family, which is characterized by its ability to activate Rho GTPases. Rho GTPases are critical molecular switches that regulate a wide array of cellular processes, including actin cytoskeleton organization, cell migration, proliferation, differentiation, and apoptosis.RhoGEF39 functions as a guanine nucleotide exchange factor specifically for Rho GTPases, facilitating the exchange of GDP for GTP to activate these GTPases. Once activated, Rho GTPases can interact with a variety of downstream effectors to elicit cellular responses. The specific GTPases that RhoGEF39 interacts with and activates can vary, but members of the Rho family, such as RhoA, Rac1, and Cdc42, are common targets.
The precise biological roles of RhoGEF39 are still being uncovered, but it is known to play a part in signaling pathways that control cytoskeletal dynamics. This includes the regulation of cell morphology, adhesion, and motility, which are fundamental for processes such as tissue development and wound healing. RhoGEF39 may also influence cell cycle progression and cellular transformation, implicating it in cancer biology.Furthermore, RhoGEF39 can be involved in the cross-talk between different signaling pathways, integrating external signals to coordinate appropriate cellular responses. Dysregulation of RhoGEF39 activity has potential implications for various pathological conditions, including cancer metastasis, due to its role in modulating cell migration and invasion.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rhosin | 1173671-63-0 | sc-507401 | 25 mg | $555.00 | ||
A selective inhibitor of Rho GTPase activity, Rhosin directly binds to RhoA and inhibits the RhoA interaction with Rho GEFs, potentially affecting pathways regulated by ARHGEF39. | ||||||
CCG-1423 | 285986-88-1 | sc-205241 sc-205241A | 1 mg 5 mg | $30.00 $90.00 | 8 | |
Targets the RhoA/serum response factor (SRF) signaling pathway, inhibiting the transcriptional activity induced by RhoA activation, which could indirectly influence ARHGEF39-regulated processes. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $148.00 $597.00 | 75 | |
Specifically inhibits Rac1 activation by blocking its interaction with Rac-specific GEFs, affecting cell motility and potentially other processes influenced by ARHGEF39 through its role in Rac activation. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
A ROCK inhibitor, Y-27632 inhibits the downstream effector of RhoA, potentially altering cellular functions influenced by ARHGEF39-mediated activation of RhoA. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $134.00 $502.00 | 7 | |
A selective inhibitor of Cdc42, another member of the Rho GTPase family, ML141 could indirectly affect cellular dynamics and processes where ARHGEF39 plays a role in Cdc42 activation. | ||||||
PHA-848125 | 802539-81-7 | sc-364581 sc-364581A | 5 mg 10 mg | $304.00 $555.00 | ||
A specific Trio (a Rho GEF) inhibitor, which indirectly might impact ARHGEF39 functions by modulating similar pathways, especially in processes where multiple GEFs contribute to the regulation of Rho GTPases. | ||||||